Articles

Company Articles and Overviews

ProQR Therapeutics: What's Bigger, Its Pipeline Or Its 2019 Outlook?

The company has several upcoming catalysts in 2019. In January, an agreement was reached with the FDA on the design of the pivotal Phase II/III ILLUMINATE trial, FDA cleared the IND application for QR-421a for Usher syndrome type 2 and non-syndromic retinitis pigmentosa due to mutations in exon 13 of the USH2A gene, Phase I/II STELLAR trial, the company obtained exclusive worldwide rights for QR-1123 from Ionis Pharmaceuticals with first in human Phase I/II clinical trial in adRP patients. The WINGS first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa from mutations in exon 73 of the COL7A1 gene.

Read More
Collin BeloinComment
Madrigal Pharmaceuticals Presents Buying Opportunity

Review on current status of Madrigal Pharmaceuticals and their recent drop in share price. I believe that this company has great potential to go back to its former glory of $300 as it currently sits under $200. NASH is a major market and MDGL is ahead of most competition, a market where there is currently no FDA approved drug.

Read More
Collin BeloinComment